Introduction
The endothelium plays a crucial role in regulating vascular tone, growth, inflammatory response, coagulation, and thrombocyte adhesion. Common conditions predisposing to atherosclerosis, such as dyslipidemia, hypertension, diabetes, and smoking are associated with endothelial dysfunction, which likely in part explains why these conditions are risk factors and promote the development, progression, and complications of atherosclerosis [1, 2] .
Endothelial function has largely been assessed as impaired endothelium-dependent vasodilation, in part based on the assumption that endothelium-dependent vasomotion represents a surrogate marker for other important functions of the endothelium. An important rationale for this approach has been the observation that endothelium-derived nitric oxide (NO • ), synthesized by the endothelial NO synthase (eNOS) from the precursor L-arginine, not only is a major mediator of endothelium-dependent vasodilation but also is critically involved in the regulation of other protective properties of the healthy endothelium [1] . Accumulating clinical studies suggest that impaired endotheliumdependent vasodilation is closely associated with cardiovascular events as described below, thereby further supporting the concept that impaired endotheliumdependent vasodilation reflects important alterations of endothelial function.
In addition, numerous studies have now assessed the mobilization, homing, and function of endothelial progenitor cells (EPCs). Importantly, the major cardiovascular risk factors are associated with impaired function of EPCs in vitro that may result in a reduced reendothelialization and neovascularization capacity in these patients. In addition, aging impairs endothelial and EPC function [3 •• ,4 • ].
Endothelial dysfunction and atherosclerosis
Experimental studies in the late 1990s suggested that endothelial cell NO production prevents endothelial cell adhesion molecule and chemokine expression and prevents thrombocyte activation and aggregation, indicating that endothelial NO may thereby exert important C/T single-nucleotide polymorphism in the promotor region of eNOS causing impaired shear stress sensitivity of eNOS expression, is more frequent in patients with coronary disease, providing evidence that reduced shear stress-dependent eNOS activation may contribute to coronary disease.
Interestingly, in a recent large-scale study of more than 2000 healthy young adults, the number of cardiovascular risk factors was correlated with increased carotid intima-media thickening in subjects with an impaired endotheliumdependent vasodilation, but not in subjects with an enhanced endothelium-dependent vasomotion [ 
Endothelial dysfunction and heart failure
Accumulating experimental data have suggested that impaired eNOS-derived NO availability not only may lead to impaired vasomotion in patients with congestive heart failure (CHF) but also has other important pathophysiological implications, such as increased left ventricular remodeling and dysfunction in heart failure. Accumulating clinical studies suggest a close association of endothelial dysfunction with an impaired prognosis in patients with heart failure. In a study of 259 subjects with both ischemic and nonischemic CHF, both decreased flow-dependent, endothelium-mediated vasodilation and decreased exhaled NO production were associated with an increased risk of death or urgent transplantation after adjustment for other known CHF prognostic factors [19 • ]. In two further studies, impaired peripheral endothelial function was independently associated with adverse long-term outcome in patients with heart failure [20
Interestingly, in patients with decompensated heart failure a particularly severe impairment of endotheliumdependent vasomotion, likely resulting from increased oxidant stress, has been observed [22] that recovers to some extent after recompensation, raising the possibility that endothelial dysfunction may directly contribute to decompensated heart failure.
Potential role of endothelial progenitor cells
After the initial report by Asahara et al.
[23] interest has been substantial in understanding the mobilization, homing, and function of EPCs in various conditions. Circulating EPCs may represent an important endogenous repair mechanism to maintain the integrity of the endothelial monolayer and promote ischemia-induced neovascularization. 
Novel mechanistic insight into endothelial dysfunction
Increased vascular reactive oxygen species production and accumulation of the endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) have been suggested as major mechanisms causing endothelial dysfunction [1, 34, 35] . In particular, it has now been recognized that under conditions in which endothelial levels of tetrahydrobiopterin (BH4), an essential cofactor of eNOS, are deficient, eNOS becomes dysfunctional and produces superoxide rather than NO, which has been termed 'eNOS uncoupling'. Thus, eNOS may have two faces in atherosclerosis and likely in heart failure depending on tissue BH4 metabolism. Uncoupled eNOS has been associated with accelerated atherosclerotic lesion formation, which could be prevented by BH4 treatment [36] . Conversely, increased endothelial BH4 synthesis by targeted transgenic guanosine triphosphate-cyclohydrolase I overexpression has been shown to reduce endothelial dysfunction and atherosclerosis in apolipoprotein E knockout mice [37 • ].
In patients with heart failure, Dixon et al. [38] have provided evidence for dysfunctional eNOS in thrombocytes. Moreover, it has recently been observed that pressure load-induced myocardial remodeling was partially attributable to reduced BH4 and increased eNOSdependent reactive oxygen species generation [39] .
Thus, understanding of the regulation of vascular BH4 levels is an important area of research with the potential for novel therapeutic strategies.
Interventions to improve endothelial function
The vascular endothelium has emerged as an attractive therapeutic target, given accumulating data suggesting an important role of endothelial dysfunction for prognosis in vascular disease. Several approaches that have been shown to improve endothelial function are discussed here.
Life style changes
The recent INTERHEART study has underscored the important role of life style for cardiovascular risk [40] . In this respect it has been shown that weight reduction improves endothelial function in overweight adults [41] and in young obese children [42 • ]; however, diet combined with exercise training was more effective [42 • ].
Exercise training has been shown to improve endothelial function in patients with coronary disease or heart failure in the forearm, as well as in the coronary circulation [43] . 
Statins
Statins rapidly improve endothelium-dependent vasomotion in humans [46] . In a recent study, we observed that simvastatin, but not ezetimibe, therapy improved endothelial function and increased EPCs in patients with CHF, suggesting that prolonged statin treatment can exert beneficial effects on endothelial function independent of lipid lowering [47 • ].
Inhibition of angiotensin-converting enzyme inhibitor and angiotensin-1 receptor blockade
Angiotensin-converting enzyme (ACE) inhibition and angiotensin-1 receptor blockade have been shown to exert beneficial effects on endothelial function [48] , and recently angiotensin-1 receptor blockade has been shown to increase circulating EPCs [49] . First studies suggest that combined statin and ACE inhibitor or angiotensin-1 receptor blocker treatment is more effective in improving endothelial function than single therapy [50, 51] ; however, more studies in different patient populations are needed to address the effect of combined treatment.
High-density lipoprotein cholesterol
There is an increasing interest in understanding the effects of high-density lipoprotein (HDL) cholesterol on vascular function. HDL has recently been shown to stimulate eNOS, partly through binding to scavenger receptor, class B type I, which is expressed in endothelial cells [52] and the lysophospholipid receptor sphingosine-1-phosphate (S1P) 3 [53] . Acute administration of HDL has been shown to improve endothelial function in hypercholesterolemic men [54] . Furthermore, in mice, administration of human HDL increased myocardial perfusion that was dependent on eNOS, since it was not observed in eNOS-deficient mice [55] . Therefore, interventions that increase HDL have the potential to improve endothelial function and myocardial perfusion.
Acyl-CoA: cholesterol acyltransferase
There are additional potential targets in lipid metabolism that may be important for the regulation of endothelial function. The Acyl-CoA:cholesterol acyltransferase (ACAT) enzymes, discovered about 7 years ago, mediate intracellular esterification of cholesterol. In a first clinical study it has been shown that ACAT inhibition improved resistancevessel endothelial function in hypercholesterolemic subjects, with small effects on circulating cholesterol [56] .
Conclusion
Accumulating data suggest a close association of endothelial dysfunction and possibly EPC levels with cardiovascular events, supporting the concept that alterations in endothelial and EPC function play an important pathophysiological role and promote development and complications of vascular disease. Current strategies to reduce cardiovascular events in patients at risk, including life style changes such as weight loss and increased physical activity as well as pharmacologic interventions with statins, ACE inhibitors, or angiotensin-1 receptor antagonists, are associated with improved endothelial function. Novel strategies to improve endothelial function may therefore have the potential to improve prognosis in vascular disease.
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